BioPlus Acquisition Valuation
Is BIOS.U undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOS.U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BIOS.U's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BIOS.U's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOS.U?
Key metric: As BIOS.U is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BIOS.U's PE Ratio? | |
|---|---|
| PE Ratio | 36.1x |
| Earnings | US$5.79m |
| Market Cap | US$209.07m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does BIOS.U's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.5x | ||
KVAC Keen Vision Acquisition | 25.2x | n/a | US$210.5m |
IVCB Investcorp Europe Acquisition Corp I | 40.6x | n/a | US$207.7m |
PRPC CC Neuberger Principal Holdings III | 34.9x | n/a | US$214.6m |
JGGC Jaguar Global Growth Corporation I | 9.4x | n/a | US$217.4m |
BIOS.U BioPlus Acquisition | 36.1x | n/a | US$209.1m |
Price-To-Earnings vs Peers: BIOS.U is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the peer average (26.3x).
Price to Earnings Ratio vs Industry
How does BIOS.U's PE Ratio compare vs other companies in the US Capital Markets Industry?
| 23 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
ADX Adams Diversified Equity Fund | 3.6x | n/a | US$2.28b |
CET Central Securities | 4.6x | n/a | US$1.32b |
GAM General American Investors Company | 4.2x | n/a | US$1.17b |
MUDS Mudrick Capital Acquisition Corporation II | 3.4x | n/a | US$401.64m |
| 23 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: BIOS.U is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the US Capital Markets industry average (27.1x).
Price to Earnings Ratio vs Fair Ratio
What is BIOS.U's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIOS.U's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Guild Holdings
US$844.7m
Guild Holdings Company originates, sells, and services residential mortgage loans in the United States.
GHLD
US$13.79
7D
-1.4%
1Y
12.6%
Qifu Technology
US$5.4b
Operates credit-tech platform under the 360 Jietiao brand in the People’s Republic of China.
QFIN
US$33.85
7D
4.9%
1Y
115.6%
VEF
SEK 2.2b
A venture capital firm specializing in early venture, emerging growth and growth capital investments.
VEFF.F
SEK 0.20
7D
0%
1Y
n/a